Marker Therapeutics Inc (MRKR)

[hanscott]

Re. Sellas Life Sciences AML clinical trials.

They use a WT1 vaccine and are targeting a different patient population than MRKR - AML patients who "Are not candidates at the time of study entry for allogeneic stem cell transplant (Allo-SCT)." MRKR is targeting AML patients post-Allo stem cell transplantation.

For their PI/II clinical trial: they tested their WT1 vaccine in combination with pembrolizumab/Keytruda, an antibody that acts as a PD1 checkpoint inhibitor (PD1 is a receptor on T Cells, which when activated by tumor cells shuts down T cell activation).

For their PIII clinical trial they are comparing their WT1 vaccine alone to several "best available" chemotherapies.

-----------------------------

I'd love to see multipronged attack using MRKR's therapy combined with checkpoint inhibitors like Keytruda (PD1 inhibitor) and/or AK117 (CD47 inhibitor) - and something like ImmunoGen's CD123-targeting Antibody-Drug-Conjugate that kills AML cells.